TARS

SEC source: 0001819790-25-000057 · wk-form4_1742521746.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,057

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001819790-25-000058 · wk-form4_1742521768.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,660

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001819790-25-000055 · wk-form4_1742521708.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,720

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001819790-25-000056 · wk-form4_1742521727.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,751

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001819790-25-000054 · wk-form4_1742521688.xml · nonDerivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,871

F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

SEC source: 0001819790-25-000047 · wk-form4_1742348431.xml · derivative · entry 2

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

Underlying: Common Stock · 8,019 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000047 · wk-form4_1742348431.xml · nonDerivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,155

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 5

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,364

Underlying: Common Stock · 23,121 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 4

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,950

Underlying: Common Stock · 16,975 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · derivative · entry 3

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,300

Underlying: Common Stock · 11,299 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000046 · wk-form4_1742348409.xml · nonDerivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001819790-25-000045 · wk-form4_1742348387.xml · derivative · entry 4

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,527

Underlying: Common Stock · 7,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000045 · wk-form4_1742348387.xml · derivative · entry 3

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,497

Underlying: Common Stock · 7,248 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000045 · wk-form4_1742348387.xml · derivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,463

Underlying: Common Stock · 4,462 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025 and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000045 · wk-form4_1742348387.xml · nonDerivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,066

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

SEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 4

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,527

Underlying: Common Stock · 7,175 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 3

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,497

Underlying: Common Stock · 7,248 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · derivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,790

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000044 · wk-form4_1742348367.xml · nonDerivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.

SEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 4

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

Underlying: Common Stock · 8,019 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 3

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,296

Underlying: Common Stock · 8,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · derivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,097

Underlying: Common Stock · 5,097 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000043 · wk-form4_1742348347.xml · nonDerivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,265

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.

SEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 4

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,060

Underlying: Common Stock · 8,019 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F6 · derivative.exercise_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

F6 · derivative.expiration_date: RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 3

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,296

Underlying: Common Stock · 8,148 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

F5 · derivative.expiration_date: RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · derivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,790

Underlying: Common Stock · 4,790 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

F4 · derivative.expiration_date: RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000042 · wk-form4_1742348322.xml · nonDerivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

F2 · balance_after: Includes 590 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024.

SEC source: 0001819790-25-000030 · wk-form4_1741723288.xml · derivative · entry 2

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2032-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option vested in full on the one-year anniversary of the date of grant.

SEC source: 0001819790-25-000030 · wk-form4_1741723288.xml · nonDerivative · entry 1

Goldberg Andrew D. · CIK 0001827722 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,350

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001819790-25-000028 · wk-form4_1741382440.xml · derivative · entry 2

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,089

Underlying: Common Stock · 20,089 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000028 · wk-form4_1741382440.xml · derivative · entry 1

Whitfield Dianne C. · CIK 0001839516 · Chief Human Resources Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,628

Underlying: Common Stock · 30,628 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000027 · wk-form4_1741382377.xml · derivative · entry 2

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,089

Underlying: Common Stock · 20,089 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000027 · wk-form4_1741382377.xml · derivative · entry 1

Farrow Jeffrey S · CIK 0001405253 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,628

Underlying: Common Stock · 30,628 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000026 · wk-form4_1741382357.xml · derivative · entry 2

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,098

Underlying: Common Stock · 22,098 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000026 · wk-form4_1741382357.xml · derivative · entry 1

Mottiwala Aziz · CIK 0001788542 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,691

Underlying: Common Stock · 33,691 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000025 · wk-form4_1741382334.xml · derivative · entry 2

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,089

Underlying: Common Stock · 20,089 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000025 · wk-form4_1741382334.xml · derivative · entry 1

Neervannan Seshadri · CIK 0001827584 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,628

Underlying: Common Stock · 30,628 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000023 · wk-form4_1741382286.xml · derivative · entry 2

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,089

Underlying: Common Stock · 20,089 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000023 · wk-form4_1741382286.xml · derivative · entry 1

Wahl Bryan · CIK 0001841401 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,628

Underlying: Common Stock · 30,628 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000022 · wk-form4_1741382259.xml · derivative · entry 2

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,512

Underlying: Common Stock · 59,512 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000022 · wk-form4_1741382259.xml · derivative · entry 1

Azamian Bobak R. · CIK 0001827672 · Director · President/CEO and Board Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,736

Underlying: Common Stock · 90,736 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000021 · wk-form4_1741382232.xml · derivative · entry 2

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,045

Underlying: Common Stock · 10,045 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

SEC source: 0001819790-25-000021 · wk-form4_1741382232.xml · derivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,314

Underlying: Common Stock · 15,314 shares

Expires 2035-03-04

F1 · derivative.exercise_date: 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

SEC source: 0001819790-24-000135 · wk-form4_1731706621.xml · derivative · entry 2

Goodrich Katherine · CIK 0002044770 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,700

Underlying: Common Stock · 6,700 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on December 15th of each of 2025, 2026, and 2027, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on December 15th of each of 2025, 2026, and 2027, subject to the Reporting Person's continuous service.

SEC source: 0001819790-24-000135 · wk-form4_1731706621.xml · derivative · entry 1

Goodrich Katherine · CIK 0002044770 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-11-12

F1 · derivative.exercise_date: The option shares will vest in three equal annual installments beginning on November 13, 2025, subject to the Reporting Person's continuous service.

SEC source: 0001819790-24-000121 · wk-form4_1730929222.xml · derivative · entry 2

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,278

Underlying: Common Stock · 27,278 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

SEC source: 0001819790-24-000121 · wk-form4_1730929222.xml · derivative · entry 1

Lin Elizabeth Yeu · CIK 0001842190 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,074

Underlying: Common Stock · 41,074 shares

Expires 2034-11-03

F1 · derivative.exercise_date: Option granted in connection with the Reporting Person's appointment as Chief Medical Officer as disclosed in the Form 8-K dated November 5, 2024.

SEC source: 0001819790-24-000115 · wk-form4_1727904418.xml · nonDerivative · entry 1

Morrison Scott W · CIK 0001662426 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · ownership.direct: The Reporting Person transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust for no consideration. The Reporting Person is trustee of the Morrison-Minton Family 2004 Trust, and the Reporting Person and his spouse are the sole beneficiaries of the trust.

SEC source: 0001819790-24-000113 · wk-form4_1726609924.xml · derivative · entry 2

Morrison Scott W · CIK 0001662426 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,334

Underlying: Common Stock · 1,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2 · derivative.exercise_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service.

F2 · derivative.expiration_date: The RSUs vest in three equal annual installments on September 15th of 2023, 2024, and 2025, subject to the Reporting Person's continuous service.

SEC source: 0001819790-24-000113 · wk-form4_1726609924.xml · nonDerivative · entry 1

Morrison Scott W · CIK 0001662426 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.